Amalgamated Bank Reduces Position in Amedisys, Inc. (NASDAQ:AMED)

Amalgamated Bank cut its holdings in shares of Amedisys, Inc. (NASDAQ:AMEDGet Rating) by 0.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,055 shares of the health services provider’s stock after selling 97 shares during the quarter. Amalgamated Bank’s holdings in Amedisys were worth $4,144,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in AMED. Mackenzie Financial Corp lifted its holdings in Amedisys by 39,235.8% during the fourth quarter. Mackenzie Financial Corp now owns 570,369 shares of the health services provider’s stock valued at $92,331,000 after purchasing an additional 568,919 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Amedisys by 23.5% during the first quarter. JPMorgan Chase & Co. now owns 1,384,041 shares of the health services provider’s stock valued at $238,457,000 after buying an additional 263,275 shares during the period. Schroder Investment Management Group increased its position in shares of Amedisys by 937.3% during the fourth quarter. Schroder Investment Management Group now owns 187,883 shares of the health services provider’s stock valued at $30,415,000 after buying an additional 169,770 shares during the period. Frontier Capital Management Co. LLC increased its position in shares of Amedisys by 98.3% during the first quarter. Frontier Capital Management Co. LLC now owns 340,741 shares of the health services provider’s stock valued at $58,706,000 after buying an additional 168,949 shares during the period. Finally, BlackRock Inc. increased its position in shares of Amedisys by 3.7% during the first quarter. BlackRock Inc. now owns 3,896,785 shares of the health services provider’s stock valued at $671,378,000 after buying an additional 138,484 shares during the period. 93.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AMED has been the topic of several analyst reports. Cowen decreased their price target on Amedisys to $125.00 in a research report on Tuesday, August 9th. Deutsche Bank Aktiengesellschaft decreased their price target on Amedisys from $210.00 to $175.00 and set a “buy” rating on the stock in a research report on Tuesday, June 21st. SVB Leerink decreased their price objective on shares of Amedisys from $117.00 to $107.00 and set a “market perform” rating on the stock in a research report on Tuesday, June 21st. Bank of America cut shares of Amedisys from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $145.00 to $102.00 in a research report on Tuesday, June 21st. Finally, Royal Bank of Canada decreased their price objective on shares of Amedisys from $199.00 to $165.00 in a research report on Friday, July 29th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $156.25.

Amedisys Stock Down 3.2 %

Shares of NASDAQ AMED opened at $111.00 on Thursday. Amedisys, Inc. has a one year low of $101.61 and a one year high of $188.88. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.92 and a quick ratio of 0.92. The firm’s 50 day simple moving average is $121.75 and its two-hundred day simple moving average is $129.77. The stock has a market capitalization of $3.60 billion, a P/E ratio of 25.87, a PEG ratio of 2.90 and a beta of 0.95.

Amedisys (NASDAQ:AMEDGet Rating) last released its quarterly earnings data on Wednesday, July 27th. The health services provider reported $1.47 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.24. The firm had revenue of $557.89 million during the quarter, compared to analyst estimates of $583.12 million. Amedisys had a return on equity of 17.81% and a net margin of 6.33%. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.69 earnings per share. As a group, analysts expect that Amedisys, Inc. will post 5.33 EPS for the current fiscal year.

Amedisys Profile

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Further Reading

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMEDGet Rating).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.